Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study.

ABSTRACT:

Background

Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alter central trigeminal pain processing; (ii) responders to galcanezumab treatment would show specific hypothalamic modulation in contrast to non-responders; and (iii) the ligand and the receptor antibody differ in brain responses.

Methods

Using an established trigeminal nociceptive functional magnetic imaging paradigm, 26 migraine patients were subsequently scanned twice: before and 2-3 weeks after administration of galcanezumab.

Results

We found that galcanezumab decreases h

SUBMITTER: Basedau H 

PROVIDER: S-EPMC9126581 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature